Truly Labs AB include Lumito’s tissue analysis technology into its customer offering
Lumito AB (publ) (“Lumito” or the “Company”) today announces that Truly Labs AB (“Truly Labs”), following an evaluation period, has decided to include SCIZYS, Lumito’s product for advanced tissue analysis, in its service offering to research and pharmaceutical clients. The decision follows the pilot study jointly conducted by Lumito and Truly Labs earlier this year. […]
Last day of trading with unit rights in Lumito’s rights issue
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Lumito AB and Katana Labs GmbH sign Letter of Intent and enter into a strategic partnership to enhance biomarker detection and quantification
Lumito AB (publ) ("Lumito" or the "Company") today announces that the Company and Katana Labs GmbH (“Katana Labs”) have signed a Letter of Intent (“LOI) formalising a strategic partnership to jointly commercialise an end-to-end, ultra-sensitive immunohistochemistry (IHC) workflow that integrates Lumito’s labelling and scanning technology with Katana Labs’ AI-powered image analysis platform. This is a […]
Investor presentation from Financial Stockholm is now available
Lumito AB’s (publ) ("Lumito" or the "Company") CEO Sanna Wallenborg presented the Company, the ongoing rights issue, and future plans at Financial Stockholm's event in Stockholm yesterday. The presentation is now available on Lumito’s website. On the website, the Company has also published other material connected to the ongoing rights issue. Click here to take […]
Lumito presents at Financial Stockholm on the 21st of October
Lumito AB (publ) ("Lumito" or the "Company") is currently conducting a rights issue, with a subscription period ending on the 30th of October 2025. Lumito's CEO, Sanna Wallenborg, will present the Company, the rights issue, and future plans at Financial Stockholm's event at Hotel Scandic Anglais in Stockholm on the 21st of October 2025. Financial […]
The subscription period in Lumito’s rights issue of units starts today
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Concept Life Sciences adds Lumito’s tissue analysis solution to its customer offering following positive results from the SCIZYS platform evaluation
Lumito AB (publ) ("Lumito" or the "Company") announces that Concept Life Sciences, a leading contract research organisation (CRO) serving the global life sciences and pharma industry, has added Lumito's advanced tissue analysis technology to its customer offering,following a joint development collaboration leading to positive results from its evaluation of the SCIZYS platform. "This is an […]
Lumito AB publishes prospectus in connection with rights issue of units of approximately SEK 60 million
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Lumito AB announces terms of rights issue of units of approximately SEK 60 million
THE INFORMATION IN THIS PRESS RELEASE MAY NOT BE ANNOUNCED, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED KINGDOM, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE THE RELEASE, PUBLICATION OR DISTRIBUTION OF THE INFORMATION WOULD BE CONTRARY TO OR REQUIRE […]
Lumito AB publishes white paper on the use of SCIZYS for high-sensitivity analysis of the breast cancer biomarker HER2 in tissue
Lumito AB (publ) (“Lumito” or the “Company”) has published a white paper highlighting how the Company’s product, SCIZYS, can be used to identify and quantify biomarkers, with a particular focus on the breast cancer biomarker HER2 at very low levels. The ability to measure extremely low HER2 levels has become increasingly important in recent years, […]